Targeting neutrophils extracellular traps (NETs) reduces multiple organ injury in a COVID-19 mouse model

Autor(es):Mostrar menos -

Veras, Flavio P. ; Gomes, Giovanni F. ; Silva, Bruna M. S. ; Caetite, Diego B. ; Almeida, Cicero J. L. R. ; Silva, Camila Meirelles S. ; Schneider, Ayda H. ; Corneo, Emily S. ; Bonilha, Caio S. ; Batah, Sabrina S. ; Martins, Ronaldo ; Arruda, Eurico ; Fabro, Alexandre T. ; Alves-Filho, Jose C. ; Cunha, Thiago M. ; Cunha, Fernando Q.

• Tipo de documento: Artigo Científico
• Fonte: RESPIRATORY RESEARCH; v. 24, n. 1, p. 11-pg., 2023-03-02.

Resumo

BackgroundCOVID-19 is characterized by severe acute lung injury, which is associated with neutrophil infiltration and the release of neutrophil extracellular traps (NETs). COVID-19 treatment options are scarce. Previous work has shown an increase in NETs release in the lung and plasma of COVID-19 patients suggesting that drugs that prevent NETs formation or release could be potential therapeutic approaches for COVID-19 treatment.MethodsHere, we report the efficacy of NET-degrading DNase I treatment in a murine model of COVID-19. SARS-CoV-2-infected K18-hACE2 mice were performed for clinical sickness scores and lung pathology. Moreover, the levels of NETs were assessed and lung injuries were by histopathology and TUNEL assay. Finally, the injury in the heart and kidney was assessed by histopathology and biochemical-specific markers.ResultsDNase I decreased detectable levels of NETs, improved clinical disease, and reduced lung, heart, and kidney injuries in SARS-CoV-2-infected K18-hACE2 mice. Furthermore, our findings indicate a potentially deleterious role for NETs lung tissue in vivo and lung epithelial (A549) cells in vitro, which might explain part of the pathophysiology of severe COVID-19. This deleterious effect was diminished by the treatment with DNase I.ConclusionsTogether, our results support the role of NETs in COVID-19 immunopathology and highlight NETs disruption pharmacological approaches as a potential strategy to ameliorate COVID-19 clinical outcomes. (AU)

• Processo FAPESP: 13/08216-2 - CPDI - Centro de Pesquisa em Doenças Inflamatórias
• Beneficiário: Fernando de Queiroz Cunha
• Modalidade de apoio: Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs
• Processo FAPESP: 20/05601-6 - Neutrophil extracelular traps (NETs): importância na patogênese e potencial alvo terapêutico na COVID-19
• Beneficiário: Fernando de Queiroz Cunha
• Modalidade de apoio: Auxílio à Pesquisa - Regular